U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846424) titled 'SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer' on Feb. 17.
Brief Summary: This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer, and to explore the pharmacokinetic characteristics, biomarker changes and immunogenicity of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer.
In this study, two ...